Plant Name: Ruta graveolens
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.836E-12 | 6.175E-09 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.380E-12 | 1.065E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.225E-11 | 5.852E-08 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.224E-11 | 1.124E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.782E-10 | 4.575E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-09 | 1.542E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.812E-09 | 1.793E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 7.115E-09 | 5.533E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.901E-09 | 6.955E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.733E-09 | 6.955E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.632E-08 | 1.791E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.666E-08 | 2.348E-05 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.493E-08 | 4.866E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.904E-07 | 1.542E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.882E-06 | 8.536E-04 | CYP2A13, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 2.274E-03 | CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.035E-05 | 3.955E-03 | CA1, CA12, CA13, CA4, CA5A, CA6, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.558E-05 | 9.131E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, RAB9A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.267E-23 | 4.936E-19 | CA1, CA12, CA13, CA14, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.134E-18 | 3.412E-14 | CA1, CA12, CA13, CA14, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.366E-16 | 7.435E-13 | CA1, CA12, CA13, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.161E-14 | 7.842E-11 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.038E-23 | 1.029E-20 | CA12; CA1; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.775E-10 | 2.279E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.341E-10 | 2.279E-08 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.090E-09 | 3.487E-08 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.112E-08 | 1.565E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.685E-06 | 3.596E-05 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.481E-05 | 2.708E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.546E-04 | 5.044E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.682E-04 | 1.111E-02 | LMNA; MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.380E-03 | 2.226E-02 | MAPK1; NFKB1; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.676E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.751E-03 | 2.038E-02 | CYP2A6; CYP3A4 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.960E-03 | 2.226E-02 | MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.676E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.157E-03 | 2.226E-02 | CYP2C9; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.569E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.569E-03 | 2.226E-02 | MAPK1; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.769E-03 | 2.226E-02 | CYP1A2; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.232E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.676E-03 | 2.226E-02 | MAPK1; HIF1A |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.348E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.464E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.348E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.348E-03 | 2.226E-02 | MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.163E-03 | 3.455E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.393E-03 | 2.923E-02 | MAPK1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.163E-03 | 3.455E-02 | MAPK1; HIF1A |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 9.787E-03 | 3.579E-02 | ACHE; MAPK1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.583E-03 | 2.256E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.959E-03 | 3.475E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 5.982E-03 | 2.836E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.636E-03 | 3.455E-02 | MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 8.636E-03 | 3.455E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.619E-03 | 3.579E-02 | MAPK1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.100E-02 | 3.729E-02 | MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.595E-02 | 4.748E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.100E-02 | 3.729E-02 | MAPK1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.136E-02 | 3.729E-02 | MAPK1; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.136E-02 | 3.729E-02 | MAPK1; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.362E-02 | 4.314E-02 | MAPK1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.442E-02 | 4.393E-02 | RAB9A; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.382E-02 | 4.314E-02 | MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.649E-02 | 4.796E-02 | MAPK1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.751E-05 | 2.801E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA1; CA9; NFKB1; ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9 |